P
Prelude Therapeutics Incorporated (PRLD)
3.05
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
3.05
0.00 (0.00%)
Prelude Therapeutics Incorporated, klinik bosqichdagi aniq onkologiya kompaniyasi, kam ta'minlangan bemorlar uchun yangi aniq saraton dorilarini kashf qilish va ishlab chiqishga qaratilgan. Kompaniya miyeloproliferativ neoplazmalar, mielofibroz (MF), polisitemiya vera va essensial trombotsitemiya (ET)ni davolash uchun JAK2V617F, genetik mutatsiya mahsulotini; ilg'or ko'krak bezi saratoni va boshqa qattiq o'smalarni davolash uchun KAT6Ani; hamda MF va ETni davolash uchun mutatsiyaga uchragan kalretikulin degrader antikor konjugatlarini ishlab chiqmoqda. Kompaniya AbCellera Biologics bilan yangi degrader antikor konjugatlarini kashf qilish, ishlab chiqish va tijoratlashtirish bo'yicha hamkorlik qiladi. Prelude Therapeutics Incorporated 2016-yilda tashkil etilgan va Uilmington, Delaver shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrew P. Combs Ph.D. | Executive VP & Chief Chemistry Officer |
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, CEO & Director |
| Dr. Madhu Pudipeddi Ph.D. | Senior Vice President of Technical Operations |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer |
| Dr. Wan-Jen Hong M.D. | Senior Vice President of Clinical Development |
| Mr. Bryant David Lim J.D. | CFO & Chief Legal Officer |
| Mr. Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-12 | 8-K | d916869d8k.htm |
| 2026-03-10 | 10-K | prld-20251231.htm |
| 2026-02-03 | 8-K | prld-20260129.htm |
| 2026-01-09 | 8-K | prld-20260109.htm |
| 2025-12-10 | S-3 | prelude_s3.htm |
| 2025-11-12 | 10-Q | prld-20250930.htm |
| 2025-11-04 | 8-K | a8k.htm |
| 2025-10-17 | 8-K | prld-20251015.htm |
| 2025-09-19 | 8-K | prld-20250918.htm |
| 2025-08-14 | 10-Q | prld-20250630.htm |
| Mr. Robert A. Doody Jr. | Senior Vice President of Investor Relations |
| Ms. Aimee Crombie Ph.D. | Senior VP and Head of Strategic Planning & Operations |
| Ms. Michele Porreca M.B.A. | Chief People Officer |